Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and individuals with ARDs not exposed to RTX.

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Although the mother and her breastmilk tested positive for CAR T cells, the baby did not, showing only normal T- and B-cell subsets.

The findings come from the global, multicenter, open-label, and single-arm Phase I/II SYRUS clinical trial (NCT06137118), ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Patients receiving Monjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months ...

The United Nations Development Programme (UNDP) has announced plans to address the members of Parliament, and parliamentary ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival ...